🚨 Trump just announced pharma tariffs to END our deadly dependence on Chinese prescription drugs.
80% of U.S. drug precursors come from China. How did past administrations allow that?
Trump's goal? Bring our medicine supply home—or pay a 200% price.
Here’s what’s coming. 🧵
2/ This is the biggest reshoring push since Trump saved U.S. Steel.
Starting later this month, tariffs will hit foreign-made pharmaceuticals.
A low tariff at first.
A 200% tariff later.
Message to Big Pharma: manufacture in America—or pay up.
3/ It’s a national security issue.
Today:
🇨🇳 China dominates active pharmaceutical ingredients (APIs).
🇮🇳 India assembles generics—but relies heavily on China too.
We’ve outsourced our health. Trump is done with that.
4/ 💊 The numbers are staggering:
– 80% of all APIs are imported
– 95% of ibuprofen
– 91% of hydrocortisone
– 70% of acetaminophen
– 45% of penicillin
That's just a start.
All from China.
This isn’t just about trade—it’s about survival in the next crisis.
5/ Trump isn’t waiting on Congress.
He signed an executive order in May streamlining FDA approval for U.S. drug factories.
And he’s ordering agencies to cut red tape and fast-track domestic production NOW.
6/ The result?
💥 Massive investments already rolling in:
– Eli Lilly: $27B for 4 U.S. plants
– J&J: $55B in new U.S. projects
– Novartis: $23B
– Roche: $50B
– Merck: $1B in Delaware
Trump’s tariff threat is WORKING.
7/ The globalists tried to reduce every issue to economics. Outsourcing your basic drug needs to China? No problem! It's all just dollars and cents!
But it isn't.
America needs to provide for our health without dependence on foreign enemies.
In a conflict, China won't care about the money. And neither will you.
If you enjoyed this content, please like and share, and also sign up for your FREE or PREMIUM subscription to my newsletter at .RodMartin.org
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.